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Abstract
Background: Little is known about pneumococcal carrier states in older adults. The main aim of this study was
to evaluate pneumococcal colonization patterns among older adults in two centres in Milan, Italy, before the
widespread use of the 13-valent pneumococcal vaccine (PCV13) in this age group, to investigate demographic and
clinical features that are associated with pneumococcal colonization and to estimate the potential coverage offered
by PCV13.
Results: Among 417 adults ≥65 years old (171, 41.1 %, ≥75 years), 41 (9.8 %) were pneumococcal carriers. Univariate and
multivariate analyses revealed that pneumococcal colonization was significantly less common among individuals with
underlying co-morbidities than among those without (odds ratio [OR] 0.453, 95 % confidence interval [CI] 0.235–0.875,
p = 0.018; adjusted OR 0.503, 95 % CI 0.255–0.992, p = 0.047). Moreover, among these patients, those with cardiac
disease had a significantly lower risk of colonization (OR 0.308, 95 % CI 0.119–0.795, p = 0.015; adjusted OR 0.341, 95 %
CI 0.13–0.894, p = 0.029). Only one vaccinated subject who received 23-valent polysaccharide pneumococcal vaccine
(PPV23) was colonized. Twenty-five (89.3 %) of the subjects who were <75 years old and 9 (75.0 %) of those who
were ≥75 years old were colonized by at least one of the serotypes that is included in PCV13, with serotype 19 F
being the most common. Respiratory allergies as well as overall co-morbidities were more common in subjects who
were positive for only non-PCV13 serotypes compared with negative subjects and those who were carriers of only
PCV13 serotypes.
Conclusions: Although this study included a relatively small number of subjects and has been performed in a limited
geographic setting, results showed that pneumococcal colonization in older people is common, and the monitoring of
carriers can offer useful information about the circulation of this pathogen among older people and the potential
protective effect of pneumococcal vaccines. Because the colonization in most cases involves the strains that are
included in PCV13, this vaccine could be useful in the prevention of pneumococcal infections in the overall population
of older people. In subjects with respiratory allergies and in those with co-morbidities, the addition of the PPV23 to
PCV13 should be recommended. Due to the low vaccination coverage, urgent educational programmes are required
to inform older adults and their medical doctors of the risks of pneumococcal infection and the efficacy and safety of
the available pneumococcal vaccines.
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Background
The clinical relevance of Streptococcus pneumoniae in
older adults has been highlighted for several years [1].
Effective vaccines and antibiotics to prevent and treat
pneumococcal infection have been developed and used
worldwide in clinical practice. This development has led
to a significant reduction in pneumococcal diseases and
has provided great benefit from medical, social and eco-
nomic viewpoints [2]. Nevertheless, S. pneumoniae re-
mains a leading cause of severe infectious diseases, with
its highest incidence in children < 2 years old and in
people ≥65 years old [1, 2]. The incidence of invasive
pneumococcal disease (IPD) is estimated to be 10-20/
100,000/year in developed countries [3, 4] and sig-
nificantly higher in the third world [5]. Moreover, pneu-
monia causes millions of deaths annually in older people
[6, 7]. This circumstance implies that further attempts to
reduce the total burden of pneumococcal infection must
be made.
Because pharyngeal pneumococcal carriage is con-
sidered to be a prerequisite for the development of
pneumococcal infections and a basis for the diffusion
of the pathogen [8], the monitoring of pneumococcal
carriage can offer relevant information about the risk
of the development of the disease, not only for the
carrier but also for the community. Moreover, because
the administration of pneumococcal conjugate vac-
cines can significantly influence colonization in both
vaccinated and unvaccinated subjects [9], the evalu-
ation of the characteristics of carriage can be ex-
tremely useful in evaluating the vaccine’s impact and
its potential direct and indirect effects. Most of the
studies in this regard were conducted with young chil-
dren. In these subjects, it has been established that
colonization rates could be as high as 75 % and
pneumococcal conjugate vaccine administration leads
to a reduction in the incidence of infections due to the
pneumococcal serotypes included in the vaccine, in
both vaccinated and unvaccinated subjects, mainly
through the impact on carriage [10]. However, little is
known about the carrier state among older adults.
Knowledge in this regard appears to be important be-
cause of the growing immunological pressure due to
the increasing vaccine coverage in children, the avail-
ability of the 23-valent polysaccharide pneumococcal
vaccine (PPV23), and the recent introduction of the
13-valent pneumococcal vaccine (PCV13) for adults
[11]. The main aim of this study was to evaluate the
pneumococcal colonization pattern among older
adults in two centres in Milan, Italy, before the wide-
spread use of PCV13 in this age group, to investigate
the demographic and clinical features that are associ-
ated with pneumococcal colonization and to estimate
the potential coverage offered by PCV13.
Results
Table 1 summarizes the general characteristics of the
417 (302, 72.4 %, females; 246, 58.9 %, <75 years old)
enrolled subjects according to their pneumococcal
colonization status. Of these subjects, 41 (9.8 %) were
pneumococcal carriers using the most effective methods
for evaluating pneumococcal colonization (i.e., oropha-
ryngeal instead of nasopharyngeal sampling, molecular
methods instead of non-enriched cultures, amplification
of both the lytA and cpsA genes instead of lytA gene
only, nylon fibre tips instead of Dacron and ryon swabs)
[12–18]. Univariate and multivariate analyses revealed
that pneumococcal colonization was significantly less
common among individuals who had underlying co-
morbidities compared with those without (odds ratio
[OR] 0.453, 95 % confidence interval [CI] 0.235–0.875,
p = 0.018; adjusted OR 0.503, 95 % CI 0.255–0.992,
p = 0.047). Moreover, among these patients, those with
cardiac disease had a significantly lower risk of
colonization (OR 0.308, 95 % CI 0.119–0.795, p = 0.015;
adjusted OR 0.341, 95 % CI 0.13–0.894, p = 0.029). By
contrast, none of the remaining studied variables were sig-
nificantly associated with pneumococcal colonization;
these studied variables were gender, ethnicity, number and
type of co-habitants, marital status, smoking habit, pres-
ence of respiratory allergy, influenza vaccination in the
previous season, mean number of respiratory infections in
the previous six months, hospitalization and admission to
the Emergency Room in the previous 3 months, and mean
number of pneumococcal infections in the previous
month. Interestingly, although there were no statistically
significant differences, individuals <75 years old was more
common among pneumococcal carriers than among
negative subjects (68.3 % vs 58.0 %; p = 0.205; ad-
justed p = 0.306), whereas antibiotic use in the previous
month was more frequent among negative subjects than
among pneumococcal carriers (12.8 % vs 2.4 %; p = 0.084;
adjusted p = 0.069). Moreover, only one subject who was
vaccinated with pneumococcal vaccine and received
PPV23 was colonized, and due to the limited number of
vaccinated subjects, it was not possible to evaluate the im-
pact of pneumococcal vaccines on carriers. Although the
association is not statistically significant, it is worthwhile
to note that previous pneumococcal vaccination reduced
the risk of pneumococcal colonization (OR 0.323, 95 % CI
0.043–2.44, p = 0.273; adjusted OR 0.389, 95 % CI 0.051–
2.969, p = 0.362).
In one out of 41 subjects with pneumococcal
colonization, serotyping was not possible. Table 2 summa-
rizes the serotypes that were carried by the 40 individuals
for whom serotyping was possible according to age group.
Twenty-five (89.3 %) of the subjects who were <75 years
old and 9 (75.0 %) of those who were ≥75 years old were
colonized by at least one of the serotypes included in
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Table 1 Characteristics of the study population and association analysis with pneumococcal colonization
Total n = 417 Negative n = 376 Positive n = 41 Odds ratio (95 % CI) p-value Adjusted odds ratio (95 % CI) p-value
Age <75 years 246 (58.99) 218 (57.98) 28 (68.29) (reference) (reference)
≥75 years 171 (41.01) 158 (42.02) 13 (31.71) 0.641 (0.322–1.276) 0.205 0.685 (0.332–1.414) 0.306
Mean age (sd) 73.97 (6.66) 74.13 (6.64) 72.49 (6.76) 0.961 (0.911–1.013) 0.135 0.969 (0.917–1.025) 0.277
Sex Male 115 (27.58) 106 (28.19) 9 (21.95) (reference) (reference)
Female 302 (72.42) 270 (71.81) 32 (78.05) 1.396 (0.644–3.023) 0.398 1.208 (0.549–2.658) 0.638
Ethnicity Caucasian 403 (96.64) 366 (97.34) 37 (90.24) (reference) (reference)
Non-Caucasian 10 (2.4) 8 (2.13) 2 (4.88) 2.473 (0.506–12.078) 0.263 1.862 (0.37–9.384) 0.451
NA 4 (0.96) 2 (0.53) 2 (4.88)
Mean number of cohabitants (sd) 0.22 (0.55) 0.23 (0.56) 0.11 (0.39) 0.563 (0.228–1.393) 0.214 0.441 (0.152–1.275) 0.131
Children cohabitants No 401 (96.16) 361 (96.01) 40 (97.56)
Yes 2 (0.48) 2 (0.53) 0 (0) NE NE NE NE
NA 14 (3.36) 13 (3.46) 1 (2.44)
Nephew No 195 (46.76) 179 (47.61) 16 (39.02) (reference) (reference)
Yes 89 (21.34) 82 (21.81) 7 (17.07) 0.955 (0.378–2.41) 0.922 0.856 (0.325–2.253) 0.753
NA 133 (31.89) 115 (30.59) 18 (43.9)
Marital status Married/Cohabiting 223 (53.48) 200 (53.19) 23 (56.1) (reference) (reference)
Single 57 (13.67) 52 (13.83) 5 (12.2) 0.836 (0.303–2.305) 0.729 0.652 (0.214–1.982) 0.451
Separated 53 (12.71) 47 (12.5) 6 (14.63) 1.11 (0.428–2.879) 0.83 1.129 (0.429–2.971) 0.806
Widowed 83 (19.9) 76 (20.21) 7 (17.07) 0.801 (0.33–1.943) 0.623 0.994 (0.395–2.503) 0.99
NA 1 (0.24) 1 (0.27) 0 (0)
Smoker No 367 (88.01) 331 (88.03) 36 (87.8) (reference) (reference)
Yes 49 (11.75) 44 (11.7) 5 (12.2) 1.045 (0.389–2.803) 0.931 0.78 (0.261–2.331) 0.657
NA 1 (0.24) 1 (0.27) 0 (0)
Respiratory allergy No 291 (69.78) 265 (70.48) 26 (63.41) (reference) (reference)
Yes 126 (30.22) 111 (29.52) 15 (36.59) 1.377 (0.703–2.7) 0.351 1.208 (0.602–2.424) 0.596
Co-morbidities No 137 (32.85) 117 (31.12) 20 (48.78) (reference) (reference)
Yes 278 (66.67) 258 (68.62) 20 (48.78) 0.453 (0.235–0.875) 0.018 0.503 (0.255–0.992) 0.047














Table 1 Characteristics of the study population and association analysis with pneumococcal colonization (Continued)
Group of co-morbidities Respiratory 86 (20.62) 79 (21.01) 7 (17.07) 0.518 (0.209–1.284) 0.156 0.613 (0.236–1.59) 0.314
Cardiac 120 (28.78) 114 (30.32) 6 (14.63) 0.308 (0.119–0.795) 0.015 0.341 (0.13–0.894) 0.029
Metabolic 23 (5.52) 20 (5.32) 3 (7.32) 0.877 (0.238–3.229) 0.844 0.945 (0.255–3.51) 0.933
Tumours 10 (2.4) 10 (2.66) 0 (0) NE NE NE NE
Thyroid 23 (5.52) 20 (5.32) 3 (7.32) 0.877 (0.238–3.229) 0.844 0.848 (0.23–3.13) 0.805
Other 16 (3.84) 15 (3.99) 1 (2.44) 0.39 (0.049–3.119) 0.375 0.448 (0.055–3.639) 0.453
None 137 (32.85) 117 (31.12) 20 (48.78) (reference) (reference)
NA 2 (0.48) 1 (0.27) 1 (2.44)
Pneumococcal vaccination No 389 (93.29) 349 (92.82) 40 (97.56) (reference) (reference)
Yes 28 (6.71) 27 (7.18) 1 (2.44) 0.323 (0.043–2.44) 0.273 0.389 (0.051–2.969) 0.362
Type of vaccination PCV13 10 (2.4) 10 (2.66) 0 (0)
PPV23 17 (4.08) 16 (4.26) 1 (2.44) NE NE NE NE
NA 390 (93.53) 350 (93.09) 40 (97.56)
Influenza vaccination in the previous season No 215 (51.56) 191 (50.8) 24 (58.54) (reference) (reference)
Yes 202 (48.44) 185 (49.2) 17 (41.46) 0.731 (0.38–1.406) 0.348 0.84 (0.419–1.682) 0.623
Mean number of respiratory infections in the previous 6 months (sd) 0.9 (1.87) 0.89 (1.92) 0.97 (1.32) 1.022 (0.863–1.211) 0.798 0.998 (0.827–1.203) 0.981
Mean number of upper respiratory tract in the previous 6 months (sd) 0.61 (1.64) 0.6 (1.67) 0.74 (1.29) 1.046 (0.874–1.251) 0.625 1.005 (0.817–1.235) 0.966
Mean number of lower respiratory tract infections in the previous
6 months (sd)
0.28 (0.68) 0.29 (0.69) 0.22 (0.48) 0.823 (0.45–1.504) 0.526 0.899 (0.49–1.646) 0.729
Hospitalizations in the last 3 months No 404 (96.88) 363 (96.54) 41 (100)
Yes 13 (3.12) 13 (3.46) 0 (0) NE NE NE NE
Emergency Room visit in the last 3 months No 388 (93.05) 352 (93.62) 36 (87.8) (reference) (reference)
Yes 24 (5.76) 21 (5.59) 3 (7.32) 1.397 (0.397–4.912) 0.602 1.651 (0.46–5.928) 0.442
NA 5 (1.2) 3 (0.8) 2 (4.88)
Treatments with antibiotic in the last month No 368 (88.25) 328 (87.23) 40 (97.56) (reference) (reference)
Yes 49 (11.75) 48 (12.77) 1 (2.44) 0.171 (0.023–1.271) 0.084 0.155 (0.021–1.158) 0.069
Pneumococcal infections in the last month No 363 (87.05) 326 (86.7) 37 (90.24) (reference) (reference)
Yes 54 (12.95) 50 (13.3) 4 (9.76) 0.705 (0.241–2.063) 0.523 0.606 (0.204–1.802) 0.368
Odds ratios, with pertinent 95 % CIs and p-values, are obtained by logistic regression. Adjustment is made for age and the presence of co-morbidity, which are potentially confounding factors
95 % CI 95 % confidence interval, NA not available, NE not executable OR odds ratio, PCV13 13-valent pneumococcal vaccine, PPV23 23-valent polysaccharide pneumococcal vaccine, SD standard deviation














PCV13. In both groups, the serotype 19 F was the most
common carried serotype (85.7 and 66.7 % in subjects
who were <75 years old and ≥75 years old, respectively).
However, in six individuals, the serotypes that were
included only in the PCV13 were identified. Serotypes that
were not included in PCV13 were evidenced in 23
(82.1 %) of the subjects <75 years old and 11 (91.7 %) of
those ≥75 years old. The most common non-PCV13
serotypes were in both groups, serotypes 24 and 15
(53.6 % and 35.7 % vs 75.0 % and 41.7 % in subjects
who were <75 years old and ≥75 years old, respectively).
Globally, serotypes that were not included in PCV13 were
included in PPV23 in 55.7 % of the cases. Six patients
were positive only for non-PCV13 serotypes. None of
them was colonized only by serotypes that were included
in PPV-23.Table 3 reports the characteristics of the
subjects who were enrolled in the study, divided by the
positivity for the serotypes. Interestingly, respiratory
allergies (66.7 % vs 29.4 %, 0.0 %, and 40.0 %, p = 0.073,
adjusted p = 0.086) as well as overall co-morbidities
(100.0 % vs 68.7 %) and cardiac underlying diseases
(50.0 % vs 21.2 %) were more common in subjects who
were positive only for non-PCV13 serotypes compared
with negative subjects, those carriers of only PCV13 sero-
types. By contrast, no significant difference was observed
from comparing negative and positive subjects regardless
of the serotypes as well as comparing the three groups of
positive subjects with regard to age distribution, gender,
number and type of co-habitants, marital status, smoking
habit, previous pneumococcal vaccination, influenza
vaccination in the previous season, mean number of re-
spiratory infections in the last six months, hospitalization
and admission to the Emergency Room in the previous
3 months, antibiotic treatment in the last month, and
mean number of pneumococcal infections in the previous
month.
Discussion
In this study in which the pneumococcal carriage of sub-
jects who were ≥65 years old was evaluated in two cen-
tres in Milan, Italy, a prevalence of 9.3 % was found.
Most of the studies that have evaluated the prevalence
of pneumococcal carriage in adults have been conducted
in subjects who were younger than those included in this
research. Consequently, the comparison is difficult be-
cause the carriage prevalence in adults can vary widely,
according to the methods that are used to identify the
pathogen, behavioural issues, the composition of house-
holds, contact with children, antibiotic use and vaccine
coverage in the paediatric population. Before pneumo-
coccal conjugate vaccine introduction, in most of the
studies conducted in the developed world, colonization
rates were found to vary between 1.5 and 30 % [19–23].
However, higher values were evidenced in developing
countries such as Nigeria and Thailand, where preva-
lences of 26 and 30 % were found [24, 25]. After the
Table 2 Colonization by specific pneumococcal serotypes according to age group
Positive for serotype Total (n = 40) Age < 75 (n = 28) Age≥ 75 (n = 12) OR (95 % IC)
1 4 (10.0) 0 (0.0) 4 (33.33) NE
3 1 (2.5) 1 (3.57) 0 (0.0) NE
4 7 (17.5) 5 (17.86) 2 (16.67) 0.92 (0.152–5.566)
6A 2 (5.0) 2 (7.14) 0 (0.0) NE
9 4 (10.0) 3 (10.71) 1 (8.33) 0.758 (0.071–8.118)
19A 1 (2.5) 1 (3.57) 0 (0.0) NE
19 F 32 (80.0) 24 (85.71) 8 (66.67) 0.333 (0.067–1.652)
PCV13 serotypes 34 (85) 25 (89.29) 9 (75.0) 0.36 (0.061–2.119)
8 2 (5.0) 2 (7.14) 0 (0.0) NE
11 2 (5.0) 2 (7.14) 0 (0.0) NE
12 5 (12.5) 5 (17.86) 0 (0.0) NE
15 15 (37.5) 10 (35.71) 5 (41.67) 1.286 (0.322–5.13)
21 1 (2.5) 1 (3.57) 0 (0.0) NE
22 6 (15.0) 5 (17.86) 1 (8.33) 0.418 (0.043–4.024)
24 24 (60.0) 15 (53.57) 9 (75.0) 2.6 (0.578–11.687)
33 4 (10.0) 2 (7.14) 2 (16.67) 2.6 (0.321–21.047)
35B 1 (2.5) 1 (3.57) 0 (0.0) NE
35 F 1 (2.5) 1 (3.57) 0 (0.0) NE
Non-PCV13 serotypes 34 (85.0) 23 (82.14) 11 (91.67) 2.391 (0.249–23.009)
95 % CI 95 % confidence interval, NE not executable, OR odds ratio
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Age <75 years 246 (58.99) 218 (57.82) 5 (83.33) 20 (71.43) 3 (50)
> = 75 years 171 (41.01) 159 (42.18) 1 (16.67) 8 (28.57) 3 (50)
Mean age (sd) 73.97 (6.66) 74.18 (6.7) 69.83 (3.92) 72.32 (6.57) 72.5 (5.01)
Sex Male 115 (27.58) 106 (28.12) 2 (33.33) 4 (14.29) 3 (50)
Female 302 (72.42) 271 (71.88) 4 (66.67) 24 (85.71) 3 (50)
Ethnicity Caucasian 403 (96.64) 367 (97.35) 6 (100) 24 (85.71) 6 (100)
Non-Caucasian 10 (2.4) 8 (2.12) 0 (0) 2 (7.14) 0 (0)
NA 4 (0.96) 2 (0.53) 0 (0) 2 (7.14) 0 (0)
Mean number of cohabitants (sd) 401 (96.16) 362 (96.02) 6 (100) 27 (96.43) 6 (100)
Children cohabitants No 0.22 (0.55) 0.23 (0.56) 0 (0) 0.12 (0.44) 0.17 (0.41)
Yes 2 (0.48) 2 (0.53) 0 (0) 0 (0) 0 (0)
NA 14 (3.36) 13 (3.45) 0 (0) 1 (3.57) 0 (0)
Nephew No 195 (46.76) 180 (47.75) 1 (16.67) 11 (39.29) 3 (50)
Yes 89 (21.34) 82 (21.75) 1 (16.67) 4 (14.29) 2 (33.33)
NA 133 (31.89) 115 (30.5) 4 (66.67) 13 (46.43) 1 (16.67)
Marital status Married/
Cohabiting
223 (53.48) 200 (53.05) 4 (66.67) 15 (53.57) 4 (66.67)
Single 57 (13.67) 52 (13.79) 1 (16.67) 4 (14.29) 0 (0)
Separated 53 (12.71) 48 (12.73) 1 (16.67) 3 (10.71) 1 (16.67)
Widowed 83 (19.9) 76 (20.16) 0 (0) 6 (21.43) 1 (16.67)
NA 1 (0.24) 1 (0.27) 0 (0) 0 (0) 0 (0)
Smoker No 367 (88.01) 332 (88.06) 5 (83.33) 25 (89.29) 5 (83.33)
Yes 49 (11.75) 44 (11.67) 1 (16.67) 3 (10.71) 1 (16.67)
NA 1 (0.24) 1 (0.27) 0 (0) 0 (0) 0 (0)
Respiratory allergies No 291 (69.78) 266 (70.56) 6 (100) 17 (60.71) 2 (33.33)
Yes 126 (30.22) 111 (29.44) 0 (0) 11 (39.29) 4 (66.67)
Co-morbidities No 137 (32.85) 117 (31.03) 3 (50) 17 (60.71) 0 (0)
Yes 278 (66.67) 259 (68.7) 3 (50) 10 (35.71) 6 (100)
NA 2 (0.48) 1 (0.27) 0 (0) 1 (3.57) 0 (0)
Group of co-morbidities Respiratory 86 (20.62) 80 (21.22) 0 (0) 3 (10.71) 3 (50)
Cardiac 120 (28.78) 114 (30.24) 1 (16.67) 4 (14.29) 1 (16.67)
Metabolic 23 (5.52) 20 (5.31) 1 (16.67) 1 (3.57) 1 (16.67)
Tumours 10 (2.4) 10 (2.65) 0 (0) 0 (0) 0 (0)
Thyroid 23 (5.52) 20 (5.31) 1 (16.67) 2 (7.14) 0 (0)
Other 16 (3.84) 15 (3.98) 0 (0) 0 (0) 1 (16.67)
None 137 (32.85) 117 (31.03) 3 (50) 17 (60.71) 0 (0)
NA 2 (0.48) 1 (0.27) 0 (0) 1 (3.57) 0 (0)
Pneumococcal vaccination No 389 (93.29) 350 (92.84) 6 (100) 28 (100) 5 (83.33)
Yes 28 (6.71) 27 (7.16) 0 (0) 0 (0) 1 (16.67)
Type of vaccination PCV13 10 (2.4) 10 (2.65) 0 (0) 0 (0) 0 (0)
PPV23 17 (4.08) 16 (4.24) 0 (0) 0 (0) 1 (16.67)
NA 390 (93.53) 351 (93.1) 6 (100) 28 (100) 5 (83.33)
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introduction of pneumococcal conjugate vaccines into
the immunization schedule of infants and children, a
prevalence of 13.8 % was found in Native American
adults ≥65 years old [26], approximately 20 % in
adults ≥45 years old in Alaska [27], and more than 30 %
in adults 60–89 years old in The Netherlands [28]. How-
ever, it is likely that these findings do not truly represent
the prevalence of pneumococcal carriage in older adults
because they included parents of neonates, infants and
young children, which introduces a relevant bias due to
exposure to the paediatric reservoir. Moreover, as in the
case of the study by Krone et al. [28], swabs were collected
from adults with influenza-like illnesses. A lower preva-
lence of carriage was reported by Ansaldi et al. in Italy a
few years ago [29]. These authors evaluated the carriage
prevalence in a group of adults ≥60 years old who were
randomly selected among the general population and
living in a geographical area that has had a high pneumo-
coccal vaccination coverage of children for several years.
They obtained four different nasopharyngeal samples at a
1-month interval and found that the point prevalence of
carriage adjusted for age was stable between the first and
fourth time point, being 9.5, 10.7, 7.6 and 10.9 % [29]. The
data collected with our study are similar and appear to in-
dicate the real prevalence of pneumococcal carriage in the
older population. Oropharyngeal sampling was used to
collect the pharyngeal secretions because it has recently
been shown that it is a significantly better means of
detecting colonization by S. pneumoniae than the
nasopharyngeal sampling used in previous studies of
younger children [12], adolescents [13], and young adults
[14]. In addition, S. pneumoniae was identified by means
of molecular methods which, albeit with some exceptions
[15], have been found to be significantly more reliable
than the traditional non-enriched cultures used in rou-
tine practice [16]. Furthermore, to improve the detec-
tion of S. pneumoniae without increasing the risk of
false-positive results, both the lytA and cpsA genes were
amplified [14], and only the samples in which both the
genes were detected in two out of three consecutive
tests of the same swab were considered to be positive.
This approach avoided false-positive results because
only S. pneumoniae has both of these genes, whereas
different streptococci that are not capsulated but that
could colonize the oropharynx possess only the lytA
gene and not the cpsA gene [17]. Finally, previous
studies have shown that flocked nylon fibre tip ensures
the highest rate of detection of S. pneumoniae, particu-
larly compared with the more widely used Dacron and
rayon swabs [18]. However, in contrast to what has been
evidenced by Ansaldi et al. [29], in this study, no higher
prevalence of pneumococcal colonization was found in
subjects who were ≥75 years old. Moreover, the presence
of an underlying medical condition, mainly cardiac disease
and older age were associated with a lower prevalence of
pneumococcal colonization. These findings are difficult to
explain, and further studies are needed to clarify the prob-
lem, although a tendency toward higher prescriptions of
antibiotics in patients with co-morbidities and in older
patients could explain the results. Indeed, pneumococcal
colonization was lower in subjects who were treated with
a recent course of antibiotics.
Regarding pneumococcal serotypes, this study showed
that almost all of the subjects who were colonized by S.
pneumoniae were carrying a strain that was included in
PCV13, which suggests a potential positive effect of
Table 3 Characteristics of patients in the study, divided by positivity for serotypes (Continued)
Influenza vaccination No 215 (51.56) 191 (50.66) 4 (66.67) 16 (57.14) 4 (66.67)
Yes 202 (48.44) 186 (49.34) 2 (33.33) 12 (42.86) 2 (33.33)
Mean number of respiratory infections (sd) 0.9 (1.87) 0.89 (1.91) 1.4 (1.14) 0.92 (1.04) 1 (2.45)
Mean number of upper respiratory
tract infections (sd)
0.61 (1.64) 0.6 (1.67) 1 (1.22) 0.65 (0.98) 1 (2.45)
Mean number of lower respiratory
tract infections (sd)
0.28 (0.68) 0.29 (0.69) 0.4 (0.55) 0.24 (0.52) 0 (0)
Hospitalizations in the last 3 months No 404 (96.88) 364 (96.55) 6 (100) 28 (100) 6 (100)
Yes 13 (3.12) 13 (3.45) 0 (0) 0 (0) 0 (0)
Emergency Room visit in the last
3 months
No 388 (93.05) 352 (93.37) 5 (83.33) 25 (89.29) 6 (100)
Yes 24 (5.76) 22 (5.84) 0 (0) 2 (7.14) 0 (0)
NA 5 (1.2) 3 (0.8) 1 (16.67) 1 (3.57) 0 (0)
Treatments with antibiotic in the
last month
No 368 (88.25) 329 (87.27) 6 (100) 27 (96.43) 6 (100)
Yes 49 (11.75) 48 (12.73) 0 (0) 1 (3.57) 0 (0)
Pneumococcal infections in the
last month
No 363 (87.05) 327 (86.74) 6 (100) 24 (85.71) 6 (100)
Yes 54 (12.95) 50 (13.26) 0 (0) 4 (14.29) 0 (0)
NA not available, PCV13 13-valent pneumococcal vaccine, PPV23 23-valent polysaccharide pneumococcal vaccine, SD standard deviation
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vaccination with this preparation. PCV13 administration
is associated with a significant reduction in the
pharyngeal carriage of the serotypes that are included in
the vaccine, which leads to a significant reduction in the
risk of development of pneumococcal disease due to this
serotype [8]. Interestingly, it was evidenced that the
most common PCV13 serotype found in this study was
19 F, which is a serotype that is included in the 7-valent
pneumococcal conjugate vaccine (PCV7) and that
should not have been circulated considering the high
PCV7 vaccination coverage that has been reached in
children for several years in the area where the survey
was performed [6]. However, recent studies have shown
that some years after PCV7 vaccination, the protective
effect against colonization wanes due to the decline in
antibody levels, and previously vaccinated children are
re-colonized by the same serotypes that were included in
the vaccine [30]. Because high antibody levels are needed
to avoid colonization by serotype 19 F, a large number of
older children become carriers of this serotype and
spread it into the community, which favours its
colonization in older adults [31]. The majority of our
study population was colonized by serotypes included in
PCV13, which highlights that PCV13 could have a rele-
vant effect in the protection of older adults. However,
considering that the most common non-PCV13 sero-
types that were carried by older people were among the
most common cause of IPD as evidenced by recent epi-
demiological studies conducted in Europe after the
introduction of PCV13 [32], continued monitoring is
needed to evaluate their importance in the older popula-
tion. This arrangement could be of particular interest in
patients with respiratory allergy and in those with co-
morbidities who in this study were found to have the
highest prevalence of this type of colonization. However,
the real importance of PPV23 in the prevention of infec-
tions that were potentially due to serotypes included in
this vaccine and not in PCV13 is difficult to evaluate
from the data collected with this study because in con-
trast to PCV13, PPV23 does not modify pneumococcal
carriage [33]. Nevertheless, PPV23 can prevent IPD be-
cause the vaccine included serotypes that could repre-
sent an effective measure in case some of the carried
serotypes would reach the blood stream. This scenario
explains why recent recommendations on the use of
pneumococcal vaccination in adults indicate that older
patients should receive the PPV23 in addition to PCV13
[34]. Unfortunately, the low pneumococcal vaccination
coverage in our population did not permit us to analyse
the impact of pneumococcal vaccines on carriage in
older adults. However, this limited use of pneumococcal
vaccines highlights the urgent need for an educational
programme on pneumococcal prevention, which should
involve older adults and their medical doctors.
Conclusions
Although this study included a relatively small number
of subjects and has been performed in a limited geo-
graphic setting, results showed that pneumococcal
colonization in older people is common and that the
monitoring of carriers can offer useful information about
circulation of the pathogen among older people and the
potential protective effect of pneumococcal vaccines.
Due to colonization, in most of the cases with strains in-
cluded in PCV13, the use of this vaccine could be useful
in the prevention of pneumococcal infections in the
overall population of older people. In subjects with re-
spiratory allergy and in those with co-morbidities, the
addition of PPV23 to PCV13 should also be recom-
mended to reduce the risk of IPD. Due to the low vac-
cination coverage, urgent educational programmes are
required to inform older adults and their medical doc-
tors on the risks of pneumococcal infection and the effi-
cacy and safety of the available pneumococcal vaccines.
Moreover, further studies are needed to evaluate the
possible impact of serotype replacement after the univer-
sal use of PCV13 in children and older adults.
Methods
Enrolment of patients and swab collection
The study was conducted in Milan, Italy, from March 1,
2015, to July 31, 2015 and two centres for older adults,
the University of the Third Age and the Pio Albergo
Trivulzio, were involved. The first is a centre in which
retired and semi-retired people come together and learn
together, not for qualifications but for their own reward.
The second is a centre that is specifically devoted to the
diagnosis and therapy of geriatric medical problems. The
study was approved by the Ethics Committee of both
centres and by that of the Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Milan, Italy and
the Pio Albergo Trivulzio, Milan, Italy.
Subjects aged ≥65 years old who regularly attended
the centres for university lessons or periodical medical
controls were screened and enrolled. Those with an
active respiratory infection and/or who were receiving
antibiotics in the 10 days before sampling were excluded
from the study. The subjects were enrolled after written
informed consent had been obtained. After enrolment,
data regarding the medical history, including the pneu-
mococcal vaccination status, were collected on each sub-
ject and were recorded in an electronic file that was
specifically prepared for the study. Particular attention
was paid to medical events that occurred in the six
months before enrolment.
The oropharyngeal samples were obtained by trained
physicians using an ESwab kit that contained a polypro-
pylene screw-cap tube filled with 1 mL of liquid Amies
medium (Brescia, Copan, Italy). The sampling was
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conducted by pressing the tongue downward to the floor
of the mouth with a spatula and swabbing both tonsillar
arches and the posterior nasopharynx, without touching
the sides of the mouth. All of the swabs were immedi-
ately transported to the central laboratory and processed
within 2 h of arrival.
Identification of S. pneumoniae
Bacterial genomic DNA was extracted from the samples
using a NucliSENS easyMAG automated extraction
system (BioMeriéux, Bagno a Ripoli, Florence, Italy), a
250-μL sample input and a generic protocol. The DNA
was analysed for the autolysin-A-encoding gene (lytA)
and the wzg (cpsA) gene of S. pneumoniae by real-time
polymerase chain reaction (PCR), as previously de-
scribed [17]. Each sample was tested in triplicate and
was considered to be positive if at least two of the three
tests revealed the presence of both genes. The levels of
detection of the test were 16 genome copies. To maxi-
mize the sensitivity, no internal amplification control
was used in the reaction, but there was an external con-
trol. All of the positive cases were serotyped using 33
primer couples and TaqMan probes chosen on the basis
of pneumococcal epidemiology in European countries and
grouped into seventeen multiplex reactions [17, 35–37].
Real-Time amplification was performed in 25-μL reactions
that contained 2x QuantiFast Multiplex PCR kit (Qiagen
S.r.l., Mi, Italy); primers and FAM or HEX labelled probes
were used at a concentration of 250 and 150 nM,
respectively.
Analytical specificity was pre-evaluated by means
of computer-aided analyses using Primer-BLAST
(www.ncbi.nlm.nih.gov/tools/primer-blast) and BLAST
(www.blast.ncbi.nlm.nih.gov/Blast.cgi) software to com-
pare the sequences with all of the sequences listed under
bacteria and Homo sapiens.
Statistical analysis
The categorical variables were compared between
groups of pneumococcal carrier status using contingency
table analysis, reporting absolute frequencies and per-
centages. The numerical variables were summarized
using mean and standard deviation.
Univariate and multivariate ORs, together with pertin-
ent 95 % CIs and p-values, were calculated using logistic
regression models to measure the association between
the selected demographic and clinical characteristics and
the pneumococcal carrier status. Adjustment was made
for a priori defined covariates such as age (i.e., <75
or ≥75 years) and co-morbidities. All of the analyses
were two tailed, and p-values of 0.05 were considered
to be statistically significant. All of the statistical ana-
lyses were conducted using R software, version 3.1.1.
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